Cytokinetics Valuation
| CYTK Stock | USD 46.16 4.54 10.91% |
At this time, the firm appears to be undervalued. Cytokinetics shows a prevailing Real Value of $55.14 per share. The current price of the firm is $46.16. Our model approximates the value of Cytokinetics from analyzing the firm fundamentals such as Shares Outstanding of 118.01 M, operating margin of (304.11) %, and Return On Equity of -5.72 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cytokinetics' valuation include:
Price Book 60.3093 | Enterprise Value | Enterprise Value Ebitda (15.82) | Price Sales 1.7 K | Enterprise Value Revenue 1.6 K |
Undervalued
Today
Please note that Cytokinetics' price fluctuation is very steady at this time. Calculation of the real value of Cytokinetics is based on 3 months time horizon. Increasing Cytokinetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cytokinetics' intrinsic value may or may not be the same as its current market price of 46.16, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 46.16 | Real 55.14 | Target 81.71 | Hype 46.23 | Naive 43.87 |
The intrinsic value of Cytokinetics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Cytokinetics' stock price.
Estimating the potential upside or downside of Cytokinetics helps investors to forecast how Cytokinetics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cytokinetics more accurately as focusing exclusively on Cytokinetics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cytokinetics' intrinsic value based on its ongoing forecasts of Cytokinetics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cytokinetics' closest peers.
Cytokinetics Cash |
|
Cytokinetics Valuation Trend
Knowing Cytokinetics' actual value is paramount for traders when making sound investment determinations. Using both Cytokinetics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Cytokinetics Total Value Analysis
Cytokinetics is currently anticipated to have valuation of 5.23 B with market capitalization of 5.45 B, debt of 755.77 M, and cash on hands of 586.03 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cytokinetics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.23 B | 5.45 B | 755.77 M | 586.03 M |
Cytokinetics Investor Information
About 100.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 5.38. Cytokinetics had not issued any dividends in recent years. The entity had 1:6 split on the 25th of June 2013. Based on the key indicators related to Cytokinetics' liquidity, profitability, solvency, and operating efficiency, Cytokinetics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Cytokinetics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cytokinetics has an asset utilization ratio of 0.91 percent. This suggests that the Company is making $0.009135 for each dollar of assets. An increasing asset utilization means that Cytokinetics is more efficient with each dollar of assets it utilizes for everyday operations.Cytokinetics Ownership Allocation
The majority of Cytokinetics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cytokinetics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cytokinetics. Please pay attention to any change in the institutional holdings of Cytokinetics as this could imply that something significant has changed or is about to change at the company.Cytokinetics Profitability Analysis
The company reported the previous year's revenue of 7.53 M. Net Loss for the year was (526.24 M) with loss before overhead, payroll, taxes, and interest of (327.54 M).About Cytokinetics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Cytokinetics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cytokinetics based exclusively on its fundamental and basic technical indicators. By analyzing Cytokinetics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Cytokinetics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cytokinetics. We calculate exposure to Cytokinetics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cytokinetics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -290.3 M | -275.8 M | |
| Pretax Profit Margin | (80.37) | (76.35) | |
| Operating Profit Margin | (75.78) | (71.99) | |
| Net Loss | (80.37) | (76.35) | |
| Gross Profit Margin | (49.27) | (46.80) |
Cytokinetics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cytokinetics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 96.5 M |
Cytokinetics Current Valuation Indicators
Cytokinetics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Cytokinetics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cytokinetics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cytokinetics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cytokinetics' worth.When determining whether Cytokinetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Cytokinetics Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Cytokinetics Stock. Highlighted below are key reports to facilitate an investment decision about Cytokinetics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share | Quarterly Revenue Growth 0.225 | Return On Assets | Return On Equity |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.